Home LiteratureArticle Details
PMID: 17535974 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

The Journal of experimental medicine ·Vol. 204 ·No. 6 ·2007-06-11 ·Pages 1431-40

Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M, Alitalo K

Abstract

Lymphatic vessel growth, or lymphangiogenesis, is regulated by vascular endothelial growth factor-C (VEGF-C) and -D via VEGF receptor 3 (VEGFR-3). Recent studies suggest that VEGF, which does not bind to VEGFR-3, can also induce lymphangiogenesis through unknown mechanisms. To dissect the receptor pathway that triggers VEGFR-3-independent lymphangiogenesis, we used both transgenic and adenoviral overexpression of placenta growth factor (PlGF) and VEGF-E, which are specific activators of VEGFR-1 and -2, respectively. Unlike PlGF, VEGF-E induced circumferential lymphatic vessel hyperplasia, but essentially no new vessel sprouting, when transduced into mouse skin via adenoviral vectors. This effect was not inhibited by blocking VEGF-C and -D. Postnatal lymphatic hyperplasia, without increased density of lymphatic vessels, was also detected in transgenic mice expressing VEGF-E in the skin, but not in mice expressing PlGF. Surprisingly, VEGF-E induced lymphatic hyperplasia postnatally, and it did not rescue the loss of lymphatic vessels in transgenic embryos where VEGF-C and VEGF-D were blocked. Our data suggests that VEGFR-2 signals promote lymphatic vessel enlargement, but unlike in the blood vessels, are not involved in vessel sprouting to generate new lymphatic vessels in vivo.

MeSH Terms
Adenoviridae Animals Blotting, Western Bromodeoxyuridine DNA Primers Genetic Vectors/genetics Lymphangiogenesis/physiology Mice Mice, Transgenic Placenta Growth Factor Pregnancy Proteins/metabolism Receptors, Vascular Endothelial Growth Factor/metabolism Reverse Transcriptase Polymerase Chain Reaction Signal Transduction/physiology Vascular Endothelial Growth Factor A/metabolism
Chemicals
DNA Primers Pgf protein, mouse Pregnancy Proteins Vascular Endothelial Growth Factor A Placenta Growth Factor Receptors, Vascular Endothelial Growth Factor Bromodeoxyuridine
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Wirzenius Maria
Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Haartman Institute and Helsinki University Hospital, Biomedicum Helsinki, University of Helsinki, 00014 Helsinki, Finland.
Tammela Tuomas
Uutela Marko
He Yulong
Odorisio Teresa
Zambruno Giovanna
Nagy Janice A
Dvorak Harold F
Ylä-Herttuala Seppo
Shibuya Masabumi
Alitalo Kari
References (38)
38 references, click to expand
  1. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.
    Nature. 1995 Jul 6;376(6535):62-6 PMID: 7596435
  2. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
    Nat Med. 2001 Feb;7(2):199-205 PMID: 11175851
  3. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.
    Nature. 1996 Apr 4;380(6573):439-42 PMID: 8602242
  4. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
    Science. 1997 May 30;276(5317):1423-5 PMID: 9162011
  5. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries.
    Hum Gene Ther. 1997 Oct 10;8(15):1737-44 PMID: 9358023
  6. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities.
    J Biol Chem. 1998 Mar 20;273(12):6599-602 PMID: 9506953
  7. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3.
    Cancer Res. 1998 Apr 15;58(8):1599-604 PMID: 9563467
  8. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses.
    Hum Gene Ther. 1998 Aug 10;9(12):1769-74 PMID: 9721087
  9. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.
    Science. 1998 Oct 30;282(5390):946-9 PMID: 9794766
  10. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain.
    J Biol Chem. 1998 Nov 20;273(47):31273-82 PMID: 9813035
  11. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
    EMBO J. 1999 Jan 15;18(2):363-74 PMID: 9889193
  12. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3071-6 PMID: 10077638
  13. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
    J Natl Cancer Inst. 2005 Jan 5;97(1):14-21 PMID: 15632376
  14. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.
    Genome Biol. 2005;6(2):209 PMID: 15693956
  15. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
    J Exp Med. 2005 Apr 4;201(7):1089-99 PMID: 15809353
  16. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.
    Blood. 2005 Jun 15;105(12):4642-8 PMID: 15746084
  17. Angiogenesis in life, disease and medicine.
    Nature. 2005 Dec 15;438(7070):932-6 PMID: 16355210
  18. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
    EMBO J. 2001 Mar 15;20(6):1223-31 PMID: 11250889
  19. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
    Cancer Res. 2001 Mar 1;61(5):1786-90 PMID: 11280723
  20. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.
    Circ Res. 2001 Mar 30;88(6):623-9 PMID: 11282897
  21. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability.
    J Cell Sci. 2002 Jun 15;115(Pt 12):2559-67 PMID: 12045226
  22. A tumor-homing peptide with a targeting specificity related to lymphatic vessels.
    Nat Med. 2002 Jul;8(7):751-5 PMID: 12053175
  23. Lymphangiogenic gene therapy with minimal blood vascular side effects.
    J Exp Med. 2002 Sep 16;196(6):719-30 PMID: 12235206
  24. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.
    J Exp Med. 2002 Dec 2;196(11):1497-506 PMID: 12461084
  25. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice.
    Biochem Biophys Res Commun. 2003 Feb 7;301(2):371-7 PMID: 12565870
  26. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
    J Cell Biol. 2003 Jun 23;161(6):1163-77 PMID: 12810700
  27. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function.
    FASEB J. 2003 Nov;17(14):2006-13 PMID: 14597670
  28. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
    Nat Immunol. 2004 Jan;5(1):74-80 PMID: 14634646
  29. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus.
    J Virol. 1994 Jan;68(1):84-92 PMID: 8254780
  30. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.
    J Biol Chem. 1994 Oct 28;269(43):26988-95 PMID: 7929439
  31. Lymphangiogenesis in development and human disease.
    Nature. 2005 Dec 15;438(7070):946-53 PMID: 16355212
  32. Angiogenesis as a therapeutic target.
    Nature. 2005 Dec 15;438(7070):967-74 PMID: 16355214
  33. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
    J Biol Chem. 2006 Apr 28;281(17):12187-95 PMID: 16505489
  34. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.
    Am J Pathol. 2006 Aug;169(2):708-18 PMID: 16877368
  35. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.
    Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2019-26 PMID: 16794222
  36. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis.
    Blood. 2004 Nov 15;104(10):3198-204 PMID: 15271796
  37. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Cancer Res. 1999 Oct 15;59(20):5209-18 PMID: 10537299
  38. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.
    Nature. 1996 Apr 4;380(6573):435-9 PMID: 8602241
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
2007-06-11
Epub
2007-00-29
Pages
1431-40
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2118625
Subset
IM
Grants
NHLBI NIH HHS · R01 HL075183 · United States
NHLBI NIH HHS · 5 R01 HL075183-02 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com